Tag: FDA clearance

All

The FDA has accepted Revance's BLA resubmission for DaxibotulinumtoxinA for Injection, designed to treat severe glabellar lines.

RVL Pharmaceuticals reported 22% revenue growth for Upneeq in Q3 2025 and announced leadership changes to support continued expansion of the product.